4-(1,2-benzisoxazolyl)piperidine antipsychotic agents

ABSTRACT

Certain 1-substituted 4-(1,2-benzisoxazolyl)-piperidine compounds exhibit neuroleptic activity and are useful in the treatment of psychosis and anxiety.

This is a division of application Ser. No. 07/612,776, filed on Nov. 14,1990, now U.S. Pat. No. 5,147,881 issued Sep. 15, 1992.

BACKGROUND OF THE INVENTION

The present invention is directed to novel 1-substituted4-(1,2-benzisoxazolyl)piperidine compounds which exhibit neurolepticactivity and are useful in the treatment of psychosis and anxiety.

Other compounds useful in treating psychotic disorders are known. Forexample, U.S. Pat. Nos. 4,558,060 and 4,831,031 describearylpiperazinyl-ethyl or butyl heterocyclic compounds and their use inthe treatment of psychiatric disorders. European Patent Application0196132 teaches 1,2-benzisoxazol-3-yl and 1,2-benzisothiazol-3-ylderivatives useful in treating psychiatric disorders.

Although the above compounds have been discovered, there is a continualsearch in this field of art for other more effective compounds.

SUMMARY OF THE INVENTION

This invention is directed to 1-substituted4-(1,2-Benzisoxazolyl)-piperidine compounds that are useful in thetreatment of psychosis and anxiety. The compounds of this invention havethe formula ##STR1## and the pharmaceutically acceptable base saltsthereof;

wherein

X is H, halo, C₁ -C₄ alkyl, C₁ -C₄ alkoxyl or CF₃ ;

n is 2, 3 or 4; and Q is ##STR2## wherein Z is CR₂ R₃, CR₂ R₃ CR₄ R₅,CR₂ R₃ CR₄ R₅ CR₆ R₇, O or S; R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are H, or C₁-C₄ alkyl; and X₁ and X₂ are H or halo; and X₃ is H, halo, C₁ -C₄ alkyl,C₁ -C₄ alkoxyl or CF₃. Solvates (e.g. hydrates) of the above compoundsare also included within the scope of the definition of formula I.

Particularly preferred compounds are compounds of formula I wherein Z isCR₂ R₃ or CR₂ R₃ CR₄ R₅. Preferred within this group are compounds wheren is 2 and X is H or halo. Preferred within this group are compoundswhere X is halo, X₁ and X₂ are H, and R₁, R₂, R₃, R₄ and R₅ are H ormethyl.

A second preferred group of compounds of formula I are those wherein Qis phenyl substituted with thiazolyl, said thiazolyl substituted withX₃. Preferred within this group are compounds wherein n is 4 and X₃ isH, halo, or C₁ -C₄ alkyl. A preferred compound within this group is1-(4-(4-(2-methylthiazol-4-yl)phenyl)butyl)-4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine.

Other preferred compounds are5-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyloxindole,1,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidinyl)ethyloxindole,3,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidinyl)ethyl)-oxindole,or6-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl)ethyl)-1,2,3,4-tetrahydro-2(1H)-quinolinone.

The present invention is also directed to pharmaceutical compositionsfor the treatment or prevention of psychosis and anxiety, whichcomprises a compound of the formula I and in a pharmaceuticallyacceptable carrier; and to a method for the treatment or prevention ofpsychosis or anxiety which comprises administering to a person in needof such treatment or prevention a compound of the formula I in an amounteffective to treat or prevent psychosis or anxiety.

Other features and advantages will be apparent from the specificationand claims.

DETAILED DESCRIPTION OF THE INVENTION ##STR3##

Compounds of the formula I wherein X, n, Q, Z, X₁, X₂, X₃, R₁, R₂, R₃,R₄, R₅, R₆ and R₇ are as defined above may be prepared by reacting theappropriate formula V compounds wherein X is as defined above with theappropriate compounds of formula VI wherein X, n, Q, Z, X₁, X₂, X₃, R₁,R₂, R₃, R₄, R₅, R₆ and R₇ are as defined above and L is a halogen (e.g.F, Br, Cl, I) or other suitable leaving group (e.g. CH₃ SO₃,p-toluenesulfonyloxy).

The reaction is generally performed in a polar solvent such as a loweralcohol, dimethylformamide, dimethylacetamide, acetonitrile, or methylisobutyl ketone, and in the presence of a weak tertiary base such astriethylamine or an inorganic base such as sodium or potassiumcarbonate. A catalytic amount of sodium or potassium iodide may beemployed to further the degree of completion. The reaction may beconducted at a temperature within the range of about 0° C. to about 250°C., and preferably it is conducted at the reflux temperature (boilingpoint) of the chosen solvent.

The formula V compounds wherein X is as defined above may be made by amodification of a procedure disclosed in European Patent Applicationpublication no. 0196132 described by Kennis et al. Generally a formulaIV compound wherein X is as defined above and L₁ is a halogen orsuitable leaving group is cyclized under basic conditions (e.g. 50%aqueous NaOH) at elevated temperatures of about 30° C. to about 100° C.and preferably at reflux.

The compounds of formula IV wherein X and L₁ are as described above maybe made by reaction of the appropriate formula III compound wherein Xand L₁ are as defined above with hydroxylamine hydrochloride and a basesuch as triethylamine or pyridine, in an inert solvent (e.g., a polarsolvent such as a lower alcohol) under reflux conditions in the absenceof oxygen.

The compounds of formula III wherein X and L₁ are as described above maybe made by deacetylation of the appropriate formula II compound, whereinX and L₁ are as described above, by heating (e.g., at reflux) in thepresence of an acid (e.g., conc. HCl) in the presence or absence of aninert solvent (e.g., acetic acid).

The compounds of formula II wherein X and L₁ are as described above maybe made by methods known to those skilled in the art, such as by theFriedel Crafts acylation of the appropriately substituted benzene usingan N-Acetyl isonipecotoyl halide.

The compounds of formula VI wherein L, X, n, Q, Z, X₁, X₂, X₃, R₁, R₂,R₃, R₄, R₅, R₆ and R₇ are as defined above may be prepared by methodsavailable to those practicing in the art and analagous to thosedescribed in European Patent Application 0281309. Thus, compounds of theformula VI (described above) may be prepared by reducing the appropriatecompound of formula XI wherein L, X, n, Q, Z, X₁, X₂, X₃, R₁, R₂, R₃,R₄, R₅, R₆ and R₇ are as defined above, with a reducing agent such astriethylsilane in trifluoroacetic acid.

Compounds of the formula XI wherein L, X, n, Q, Z, X₁, X₂, X₃, R₁, R₂,R₃, R₄, R₅, R₆, and R₇ are as defined above may be prepared by reactingthe appropriate compound of the formula IXA or IXB wherein X, Z, X₁, X₂,X₃, R₁, R₂, R₃, R₄, R₅, R₆, and R₇ are as defined above with ahaloalkanoic acid or a haloalkanoyl halide wherein the halogen isselected from the group consisting of Cl, Br and I, employing, forexample, Friedel-Crafts conditions (e.g., aluminum trichloride in carbondisulfide or methylene dichloride under an inert atmosphere) or viaacylation in a medium such as polyphosphoric acid at a temperature fromabout room temperature to about 100° C.

Formula Q compounds having the Formula IXA wherein phenyl is substitutedwith thiazoyl (the thiazolyl is optionally substituted with X₃ asdefined above) may be made by standard methods known to those skilled inthe art such as described in Preparation E and EP Application 279,548.

Compounds of the formula IXB wherein X₁, X₂, R₁, R₂, R₃, R₄, R₅, R₆, andR₇ are as defined above and Z is CR₂ R₃, CR₂ R₃ CR₄ R₅, CR₂ R₃ CR₄ R₅CR₆ R₇ may be made by several methods as described in the literature(e.g. U.S. Pat. No. 4,831,031), and outlined above. For example, an arylamine of formula VII wherein X₁, X₂ and R₁ are as defined above may beconverted using methods known in the art, to an arylamide of the formulaVIII wherein X₁, X₂, R₁, R₂, R₃, R₄, R₅, R₆, and R₇ are as defined aboveand Q₂ is a leaving group (e.g. halo) which may then be cyclized toproduce a compound of the formula IXB.

Alternatively, compounds of formula VIII in which Z is C=0 and Q₂ ishalo (i.e., Cl or Br) may be cyclized (e.g., employing Friedel-Craftsconditions as described above) to a compound of structure XII. Thesecompounds of formula XII may then be reduced to compounds of formula IXB(where Z=CH₂) using reduction techniques known to those skilled in theart (e.g., by the Wolff-Kishner reduction, employing hydrazine and astrong base).

Compounds of the formula IXB wherein X₁, X₂, R₁ are as defined above andZ is S or O may be prepared by standard methods known to those skilledin the art (e.g., U.S. Pat. No. 4,831,031). In addition some arecommercially available (e.g., 2-Benzoxazolinone is available fromAldrich Chem. Co.)

The pharmaceutically acceptable acid addition salts of the compounds offormula I are prepared in a conventional manner by treating a solutionor suspension of the free base, i.e., a compound of formula I, withabout one chemical equivalent of a pharmaceutically acceptable acid.Conventional concentration and recrystallization techniques are employedin isolating the salts. Such pharmaceutically acceptable acid additionsalts include, but are not limited to the respective salts of acetic,malic, citric, fumaric, sulfuric, hydrochloric, hydrobromic, hydroiodic,sulfonic such as methanesulfonic and p-toluenesulfonic and relatedacids.

The neuroleptic activity of the present compounds may be demonstrated bymethods based on standard procedures. In one method, adult maleSprague-Dawley rats are pretreated with appropriate doses of the testcompound by subcutaneous injection. One half hour later all rats areinjected intraperitoneally with 1 mg/kg apomorphine hydrochloridedissolved in an 0.1% ascorbate solution. The rats are rated behaviorallyaccording to the following scale at 5, 15, 25, 35 and 45 minutes afterthe apomorphine injection: 0=alert but not moving, 1=moving around thecage, 2=discontinuous sniffing behavior, 3=continuous sniffing withdiscontinuous oral movements, and 4=continuous licking and chewingmovements.

The neuroleptic activity of the compounds of this invention makes themuseful for treating psychotic disorders in human subjects. For example,these compounds are useful for treating psychotic disorders of theschizophrenic types and in particular the compounds are useful forremoving or ameliorating such symptoms as anxiety, agitation, excessiveagression, tension and social or emotional withdrawal in psychoticpatients.

A neuroleptic compound of the formula I or a pharmaceutically-acceptablesalt thereof can be administered to a human subject either alone orpreferably in combination with pharmaceutically-acceptable carriers ordiluents in a pharmaceutical composition according to standardpharmaceutical practice. A compound can be administered orally orparenterally. Parenteral administration includes especially intravenousand intramuscular administration. Additionally, in a pharmaceuticalcomposition comprising a compound of formula I or apharmaceutically-acceptable salt thereof, the weight ratio of activeingredient to carrier will normally be in the range from about 1:6 toabout 2:1 and preferably from about 1:4 to about 1:1. However, in anygiven case, the ratio chosen will depend on such factors as thesolubility of the active component, the dosage contemplated and theprecise route of administration.

For oral use of a neuroleptic agent of this invention, the compound canbe administered, for example, in the form of tablets or capsules or asan aqueous solution or suspension. In the case of tablets for oral use,carriers which can be used include lactose and corn starch, andlubricating agents such as magnesium stearate can be added. For oraladministration in capsule form, useful diluents are lactose and driedcorn starch. When aqueous suspensions are required for oral use, theactive ingredient can be combined with emulsifying and suspendingagents. If desired, certain sweetening and/or or flavoring agents can beadded. For intramuscular and intravenous use, sterile solutions of theactive ingredient can be prepared and the pH of the solutions should besuitably adjusted and buffered. For intravenous use the totalconcentration of solutes should be controlled to render the preparationisotonic.

When a neuroleptic agent of this invention is to be used in a humansubject to treat a psychotic disorder, the daily dosage will normally bedetermined by the prescribing physician. Moreover, the dosage will varyaccording to the age, weight and response of the individual patient aswell as the severity of the patient's symptoms. However, in mostinstances an effective amount for treating a psychotic disorder will bea daily dosage in the range from about 3 mg to about 600 mg andpreferably from about 30 mg to about 60 mg in single or divided doses,orally or parenterally. In some instances, it may be necessary to usedosages outside these limits.

The present invention is illustrated by the following examples, but isnot limited to the details thereof.

EXAMPLE 15-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)oxindole

Under N₂ a mixture of 4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine V(2.0 g, 9.08 mmol), 5-(2-chloroethyl)oxindole (0.95 g, 10 mmol), Na₂ CO₃(1.06 g, 10 mmol) and KI (1.0 g, 6.0 mmol) in 45 ml dry DMF was heatedat 90° C. for 72 hours. The reaction mixture was then poured over 150 mlice/water, stirred, and filtered to give 3.04 g of brown solids.Chromatography on silica gel (230-400 mesh), eluting with 95% EtOAc: 5%triethylamine provided clean product, 0.645 g (19%), light brown solid,m.p. 199°-204° C. Analysis for C₂₂ H₂₂ FN₃ O₂ ·0.5H₂ O: C 68.03, H 5.97,N 10.82. Found: C 67.94, H 5.57, N 10.81; MS(%): 379 (1, p⁺), 253 (4),234 (32), 233 (100). NMR (300 MHz, CDCl₃, delta), 2.0-2.4 (m, 6H), 2.65(m, 2H), 2.8 (m, 2H), 3.1-3.2 (m,3H), 3.5 (s, 2H), 6.75 (d, 1H), 7.1 (m,3H), 7.2 (s, 1H), 7.7 (m, H), 8.25 (br s, 1H).

EXAMPLES 2-5

By a similar procedure the following were also prepared:

2.1,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl)ethyl)oxindolehydrochloride hydrate 35%, m.p. 104° C. (dec.). Analysis for C₂₄ H₂₆ FN₃O₂ ·HCl·1.5H₂ O: C 61.21, H 6.42, N 8.92. Found: C 61.28, H 6.40, N8.64. MS(%): 407 (3,p⁺), 233 (100).

3.3,3-dimethyl-5-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl)ethyl)oxindolehydrochloride quarterhydrate 21%, m.p. 268° C. (dec.). Analysis for C₂₄H₂₆ FN₃ O₂ ·HCl·0.25 H₂ O: C 64.28, H 6.18, N 9.37. Found: C 64.33, H5.79, N 9.10. MS(%): 407 (3, p⁺), 269(4), 233 (100).

4.6-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl)ethyl)-1,2,3,4-tetrahydro-2(1H)-quinolinonehemihydrate 50%, m.p. 193°-195° C. Analysis for C₂₃ H₂₄ FN₃ O₂. 0.5H₂ O:C 68.64, H 6.26, N 10.44. Found: C 68.65, H 5.94, N 10.13; MS(%): 393(2, p⁺), 233(100).

5.1-(4-(4-(2-methylthiazol-4-yl)phenyl)butyl)-4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinedihydrochloride hemihydrate 34%, m.p. 188°-189° C. Analysis for C₂₆ H₂₈FN₃ OS·2HCl·0.5H₂ O: C 58.75, H 5.88, N 7.91. Found: C 58.40, H 5.96, N7.80; MS(%): 451 (6), 450 (20), 449 (52,p⁺), 311 (33), 233 (100).

PREPARATION A 4-(6-Fluoro-1,2-benzisoxazol-3-yl)-piperidinehydrochloride (V)

N-Acetyl isonipecotoyl chloride (70.0 g, 0.369 mol) was added over a 20minute period to a vigorously stirred suspension of AlCl₃ (98 g, 0.735mol) in 1,3-difluorobenzene (125 ml, 1.27 mol, Aldrich Chem. Co.) at 25°C. The mixture was then refluxed, under N₂ for 4.5 hours, cooled to 25°C., and poured over 300 ml of ice/water. The layers were separated, theaqueous layer was extracted (2×100 ml CH₂ Cl₂) and combined with theorganic layer and dried with MgSO₄. Concentration in vacuo gave4-(2,4-difluorobenzoyl)-1-acetyl-piperidine (II) as a white solid (81 g,82%), m.p. 94°-96° C.

The preceding ketone (40 g, 0.15 mol) was added to a mixture of 125 mlconcentrated HCl and 125 ml acetic acid and refluxed for 16 hours,cooled, and concentrated in vacuo. The white residue was triturated withhot isopropanol, filtered, washed with Et₂ O and dried to give 32.3 g(83%) of 4-(2,4-difluorobenzoyl)-piperidine hydrochloride (III), m.p.215°-216° C.

The above material (32 g, 0.122 mol), hydroxylamine.HCl (8.5 g, 0.122mol) and triethylamine (24.8 g, 0.224 mol) in EtOH (250 ml) was refluxedunder N₂ for 4 hours, cooled and filtered to provide the oxime (IV),27.44 g (93%), m.p. 246°-252° C.

Crude IV in 300 ml of 50% aqueous NaOH was refluxed for 4 hours, cooledand extracted with toluene (3×100 ml). The organic extracts were washedwith saturated NaCl, dried (MgSO₄) and concentrated to a yellow residue.Chromatography on silica gel (230-400 mesh) eluting with 19 CH₂ Cl₂ :1CH₃ OH:0.1 NH₄ OH produced the title product (V), converted to itshydrochloride with HCl gas in Et₂ O, 5.0 g (17%), m.p. 295° C. (dec.).

PREPARATION B, C

The substituted 5-(2-chloroethyl)oxindoles used in Examples 2 and 3 wereprepared in an analagous fashion to preparation D from the appropriatestarting materials (i.e., 1,3-dimethyloxindole and 3,3-dimethyloxindole,respectively).

PREPARATION D 6-(2-chloroethyl)-1,2,3,4-tetrahydro-2(1H)-quinolinone

Under N₂ a mixture of chloroacetyl chloride (5.2 ml, 0.065 mol) andAlCl₃ (41.4 g, 0.31 mol) in 200 ml CS₂ was stirred mechanically while1,2,3,4-tetrahydro-2(1H)-quinolinone (7.36 g, 0.05 mol, preparedaccording to the method of JACS, 1944, 66, 1442) was added over a 5minute period. The mixture was refluxed for 2 hours and another 20 mlchloroacetyl chloride was added. After a further 3 hours at reflux, thedark green reaction mixture was cooled to 25° C., the CS₂ was decanted,and the residue was slowly decomposed by pouring slowly over 500 g ice.(NOTE: vigorous evolution of HCl!) The resulting solids were filtered,washed well with H₂ O and air dried to give 10.7 g (96%) of crude6-chloroacetyl-1,2,3,4-tetrahydro-2(1H)-quinolinone, m.p. 215°-218° C.;MS(%): 233 (9, p⁺), 174 (100).

Under N₂, the above intermediate (6.71 g, 0.03 mol) in trifluoroaceticacid (23 ml, 0.3 mol) was treated dropwise with triethylsilane (11 ml,0.069 mol) while maintaining an internal temperature below 25° C. After72 hours at 25° C. the brown solution was poured over 200 ml ice/waterand stirred to produce a tan solid which was further washed with waterand dried to give the title product, 5.42 g (86%), m.p. 148°-152° C.(dec.); MS(%): 211, 209 (34, p⁺), 160(100). NMR (d₆ -DMSO, 300 MHz,delta), 2.0-2.3 (m, 2H), 2.4-2.75 (m, 4H), 3.4 (t, 2H), 6.4 (d, 1H),6.6-6.8 (m, 2H), 9.7 (br s, 1H).

PREPARATION E

The chlorobutyl thiazolyl substituted phenyl used in Example 5 wasprepared according to the following method and as described in E.P.Application 279,598.

4-Chlorobutylacetophenone: To a 250 ml round-bottomed flask were added5.0 g (29.65 mmol) 1-chloro-4-phenylbutane and 10 ml 1,2-dichloroethane.To the stirred solution was added a solution of 4.35 g (32.62 mmol)aluminum chloride and 4.22 ml (59.31 mmol) acetyl chloride in 50 ml1,2-dichloroethane. The solution evolved HCl as it was stirred at roomtemperature for 1 hour. It was then poured into water, the layersseparated, and the organic layer washed with 1N HCl, aqueous sodiumbicarbonate solution, brine, dried over sodium sulfate, and evaporatedto an oil, 6.7 g (>100%). NMR (delta, CDCl₃): 1.76 (m, 4H), ˜2.5 (s,3H), 3.50 (m, 2H), 7.2 and 7.85 (m, 4H). IR cm⁻¹, neat): 1678 (C═O).

4-(4-Chlorobutyl)phenyl-2-methylthiazole hydrobromide: The above oil wasadded to a 100 ml round-bottomed flask equipped with N₂ inlet along with15 ml acetic acid. Bromine (1.53 ml, 29.65 mmol) was added dropwise andthe solution stirred at room temperature for 15 minutes (decolorizes inabout 7 minutes). The solution was taken up in ethyl acetate(careful--the bromide is a potent lachrymator), washed with water,aqueous sodium bicarbonate solution, brine, dried over sodium sulfate,and evaporated to an oil, 8.9 g (about 100% yield).

The oil was dissolved in 70 ml acetone, treated with 2.23 g (29.65 mmol)thioacetamide (which gives a precipitate, which, however, is notproduct) and refluxed 15 hours. The reaction was cooled, evaporated to10 ml volume to afford a precipitate, filtered, the precipitate washedwith 10 ml acetone, then washed thoroughly with ether and dried to awhite solid, mp 128°-129° C., 6.8 g (66.2%). NMR (delta, DMSO-d₆): 1.85(m, 4H), 2.5 (m, 2H), 2.77 (s, 3H), 3.5 (m, 2H), 7.2 and 7.8 (m, 4H),7.92 (s, 1H). IR (cm⁻¹, DMSO): 1620. MS (%): 265/267 (parent, 7.5/3.7),189 (17), 188 (100), 147 (39), 115 (11), 82 (10).

I claim:
 1. A 4-(1,2-Benzisoxazolyl)-piperidine compound of the formula##STR4## and the pharmaceutically acceptable base salts thereof whereinX is H, halo, C₁ -C₄ alkyl, C₁ -C₄ alkoxyl or CF₃ ;n is 2, 3 or 4; and Qis ##STR5## wherein Z is CR₂ R₃ CR₄ R₅, R₁, R₂, R₃, R₄ and R₅ are H orC₁ -C₄ alkyl; X₁ and X₂ are H or halo.
 2. A compound according to claim1 wherein Z is CR₂ R₃ CR₄ R₅, n is 2 and X is H or halo.
 3. A compoundaccording to claim 2 wherein X is halo, X₁ and X₂ are H, and R₁, R₂, R₃,R₄ and R₅ are H or methyl.
 4. A compound according to claim 1 saidcompound being6-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-1,2,3,4-tetrahydro-2(1H)-quinolinone.5. A pharmaceutical composition for the treatment or prevention ofpsychosis and anxiety, which comprises a compound according to claim 1in a pharmaceutically acceptable carrier.
 6. A method for the treatmentor prevention of psychosis or anxiety, comprising administering to aperson in need of said treatment or prevention a compound according toclaim 1 in an amount effective to treat or prevent psychosis or anxiety.